World News: 12:00 GMT Thursday 6th December 2018. [Athenex, Inc. via Globe Newswire via SPi World News]
BUFFALO, N.Y., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will host an R&D Day on Monday, December 17, 2018, from 12 noon to 3:00 pm Eastern Time, in New York City.
The Company will provide an overview of the R&D pipeline and updates on key clinical programs. Discussion topics will cover Athenex’s Orascovery, Src Kinase Inhibition and T Cell Receptor Engineered T Cell (TCR-T) Immunotherapy platforms. Management will also discuss commercial development strategy and the market potential of its drug candidates as novel therapies for the treatment of cancer.
This event is intended for institutional investors, sell-side analysts, investment bankers and business development professionals only. Please in advance if you plan to attend in person, as space is limited. For those unable to attend, a live webcast with slides and replay will be accessible via the page on the Investor Relations tab of the Athenex website or via this . If you would like to ask a question during the live Q&A session, please submit your request via to . A replay of the presentation will be available for 60 days following the event.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit .
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “will,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; competition; intellectual property risks; risks relating to doing business in China; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.
Athenex, Inc.: Randoll SzeChief Financial OfficerEmail:
Jacqueline LiCorporate Development and Investor RelationsEmail:
Globe Newswire: 12:00 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.